Bluejay Diagnostics Enrolls 624 Patients in SYMON-II Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy BJDX?
Bluejay Diagnostics announced the enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the company's Symphony platform for interleukin-6 testing in critical care settings to determine patient acuity for sepsis triage and monitoring. The SYMON-II study has a target enrollment of 750 patients, and the company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow. The SYMON-II trial is designed to support the clinical validation of Bluejay's Symphony IL-6 test, which aims to provide rapid, near-patient results to aid clinicians in assessing patient severity and guiding timely decision-making in acute care environments. With enrollment nearing completion, Bluejay anticipates progressing toward the next phases of clinical validation and regulatory submission activities. The Symphony IL-6 Test to determine patient acuity for sepsis triage and monitoring is currently Bluejay's lead product candidate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BJDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BJDX
About BJDX
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bluejay Diagnostics Advances SYMON-II Trial Enrollment
- Significant Trial Progress: Bluejay Diagnostics has successfully enrolled 624 patients in the SYMON-II trial, leaving only 126 to reach the target of 750, with completion expected in the next 2-3 months, reflecting strong execution by the clinical team and commitment from clinical partners.
- Clinical Validation Goals: The SYMON-II trial aims to validate the clinical efficacy of the Symphony™ IL-6 test, which provides rapid results on patient severity, thereby aiding clinicians in making timely decisions in acute care settings and improving patient outcomes.
- Market Potential: With enrollment nearing completion, Bluejay plans to advance clinical validation and regulatory submission activities, aligning with its strategy to promote near-patient testing and real-time monitoring in critical care, which is expected to positively impact the company's future market performance.
- Leading Product Candidate: The Symphony™ IL-6 test is Bluejay's first product candidate, designed to deliver rapid results in approximately 20 minutes, assisting healthcare professionals in making earlier and more effective triage and treatment decisions, showcasing significant market application potential.
See More
NORTHSTRIVE FUND II: BLUEJAY BOARD ASSESSES A STRATEGIC OPPORTUNITY RECOMMENDATION
- Strategic Opportunity: The North Strive Fund II is recommending the Blue Jay Board as a strategic opportunity for investment.
- Evaluation Process: The evaluation of the Blue Jay Board is part of a broader assessment of potential investment avenues by the North Strive Fund II.
See More
Bluejay Diagnostics Provides 2026 Strategic Update
- Clinical Progress: Bluejay Diagnostics' SYMON™ II clinical study is progressing as planned with ongoing site activities and enrollment, aimed at generating data to support the company's future regulatory strategy for effective sepsis risk assessment in critical care settings.
- Manufacturing Readiness: The company has made significant progress in critical raw materials, antibody supply, and external manufacturing coordination, which collectively reduce historical supply chain risks and support future commercialization readiness, ensuring timely product launch.
- Capital Structure Update: In February 2026, the company completed the full exercise of previously issued prefunded warrants, converting to approximately 972,000 shares of common stock, and expects to report $5.2 million in cash and $6.0 million in stockholders' equity as of December 31, 2025, reflecting strong capital management.
- Strategic Priorities: Bluejay will continue to focus on completing the SYMON™ II study, strengthening supply chain robustness and production capacity, and plans to raise at least $20 million in additional capital by the end of the 2027 fiscal year to support its long-term growth strategy.
See More
Bluejay Diagnostics Fully Exercises All Prefunded Warrants
- Warrant Exercise Completion: As of February 19, 2026, Bluejay Diagnostics has fully exercised all prefunded warrants from its October 2025 private placement, resulting in approximately 972,000 shares of common stock outstanding, indicating a proactive adjustment in the company's capital structure.
- Cash-Exercisable Warrants: The company currently has approximately 1.5 million cash-exercisable warrants outstanding, with an exercise price of $7.00 or greater per share, which provides potential opportunities for future capital raising and enhances financial flexibility.
- Reverse Stock Split Impact: The company cautions investors that recent Schedule 13G filings do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, potentially leading to misunderstandings regarding current beneficial ownership and affecting market perceptions of the company's equity structure.
- Product Candidate Progress: Bluejay's IL-6 test candidate aims to deliver rapid results in approximately 20 minutes, and although it has not yet received FDA regulatory clearance, its potential market application could significantly improve patient treatment decisions, showcasing the company's strategic foresight in the medical diagnostics field.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Bluejay Diagnostics Enrolls 545 Patients in SYMON™ II Study
- Clinical Trial Progress: Bluejay Diagnostics has successfully enrolled 545 patients in its SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations with a target of 750 patients, demonstrating strong execution in clinical recruitment, which reduces execution risk and prepares for subsequent data analysis and commercialization.
- Manufacturing Readiness: The company is advancing manufacturing readiness across multiple parallel workstreams, including antibody production and commercial manufacturing infrastructure, having completed monoclonal and polyclonal antibody production sufficient for over 10 million test cartridges, ensuring supply capacity for U.S. market production.
- Technology Transfer Progress: Technology transfer activities are progressing without a single point of failure, with management employing parallel execution strategies to mitigate timing and scale-up risks, ensuring the smooth advancement of the SYMON™ II program.
- Future Outlook: As Bluejay enters 2026, management believes the company is operating from a materially stronger execution position with reduced clinical risk, focusing on value realization through data analysis and regulatory engagement to further drive commercialization readiness.
See More
Bluejay Diagnostics Advances SYMON-II Trial Enrollment
- Significant Trial Progress: Bluejay Diagnostics has successfully enrolled 624 patients in the SYMON-II trial, leaving only 126 to reach the target of 750, with completion expected in the next 2-3 months, reflecting strong execution by the clinical team and commitment from clinical partners.
- Clinical Validation Goals: The SYMON-II trial aims to validate the clinical efficacy of the Symphony™ IL-6 test, which provides rapid results on patient severity, thereby aiding clinicians in making timely decisions in acute care settings and improving patient outcomes.
- Market Potential: With enrollment nearing completion, Bluejay plans to advance clinical validation and regulatory submission activities, aligning with its strategy to promote near-patient testing and real-time monitoring in critical care, which is expected to positively impact the company's future market performance.
- Leading Product Candidate: The Symphony™ IL-6 test is Bluejay's first product candidate, designed to deliver rapid results in approximately 20 minutes, assisting healthcare professionals in making earlier and more effective triage and treatment decisions, showcasing significant market application potential.
See More
NORTHSTRIVE FUND II: BLUEJAY BOARD ASSESSES A STRATEGIC OPPORTUNITY RECOMMENDATION
- Strategic Opportunity: The North Strive Fund II is recommending the Blue Jay Board as a strategic opportunity for investment.
- Evaluation Process: The evaluation of the Blue Jay Board is part of a broader assessment of potential investment avenues by the North Strive Fund II.
See More
Bluejay Diagnostics Provides 2026 Strategic Update
- Clinical Progress: Bluejay Diagnostics' SYMON™ II clinical study is progressing as planned with ongoing site activities and enrollment, aimed at generating data to support the company's future regulatory strategy for effective sepsis risk assessment in critical care settings.
- Manufacturing Readiness: The company has made significant progress in critical raw materials, antibody supply, and external manufacturing coordination, which collectively reduce historical supply chain risks and support future commercialization readiness, ensuring timely product launch.
- Capital Structure Update: In February 2026, the company completed the full exercise of previously issued prefunded warrants, converting to approximately 972,000 shares of common stock, and expects to report $5.2 million in cash and $6.0 million in stockholders' equity as of December 31, 2025, reflecting strong capital management.
- Strategic Priorities: Bluejay will continue to focus on completing the SYMON™ II study, strengthening supply chain robustness and production capacity, and plans to raise at least $20 million in additional capital by the end of the 2027 fiscal year to support its long-term growth strategy.
See More
Bluejay Diagnostics Fully Exercises All Prefunded Warrants
- Warrant Exercise Completion: As of February 19, 2026, Bluejay Diagnostics has fully exercised all prefunded warrants from its October 2025 private placement, resulting in approximately 972,000 shares of common stock outstanding, indicating a proactive adjustment in the company's capital structure.
- Cash-Exercisable Warrants: The company currently has approximately 1.5 million cash-exercisable warrants outstanding, with an exercise price of $7.00 or greater per share, which provides potential opportunities for future capital raising and enhances financial flexibility.
- Reverse Stock Split Impact: The company cautions investors that recent Schedule 13G filings do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, potentially leading to misunderstandings regarding current beneficial ownership and affecting market perceptions of the company's equity structure.
- Product Candidate Progress: Bluejay's IL-6 test candidate aims to deliver rapid results in approximately 20 minutes, and although it has not yet received FDA regulatory clearance, its potential market application could significantly improve patient treatment decisions, showcasing the company's strategic foresight in the medical diagnostics field.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Bluejay Diagnostics Enrolls 545 Patients in SYMON™ II Study
- Clinical Trial Progress: Bluejay Diagnostics has successfully enrolled 545 patients in its SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations with a target of 750 patients, demonstrating strong execution in clinical recruitment, which reduces execution risk and prepares for subsequent data analysis and commercialization.
- Manufacturing Readiness: The company is advancing manufacturing readiness across multiple parallel workstreams, including antibody production and commercial manufacturing infrastructure, having completed monoclonal and polyclonal antibody production sufficient for over 10 million test cartridges, ensuring supply capacity for U.S. market production.
- Technology Transfer Progress: Technology transfer activities are progressing without a single point of failure, with management employing parallel execution strategies to mitigate timing and scale-up risks, ensuring the smooth advancement of the SYMON™ II program.
- Future Outlook: As Bluejay enters 2026, management believes the company is operating from a materially stronger execution position with reduced clinical risk, focusing on value realization through data analysis and regulatory engagement to further drive commercialization readiness.
See More
